We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Cardio Diagnostics Holdings, Inc.
Health Care · Biotechnology
Structural: cardiovascular disease remains the #1 global killer; standard lipid/CRP panels miss ~50% of first-event MI patients, creating demand for next-gen biomarker screening. Epigenetic methylation signatures are reproducible and actionable earlier than genomic SNP panels.
PrecisionCHD fills a genuine diagnostic gap; direct-to-physician commercialization avoids hospital procurement drag; AI/epigenetics narrative could command premium multiple on any revenue inflection; tiny float magnifies any catalyst.
Pre-revenue microcap burning cash with no commercial-scale traction evidence; reimbursement pathway unclear (CPT coverage risk is binary); competing against established players (Quest, LabCorp, Foundation Medicine) with vastly more distribution; dilution risk severe at sub-$10M market cap.
Each weekday: the scan's ENTER setups with entry, stop and target, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
No spam. One email per day max. Pro adds Telegram trade alerts and higher AI-assistant limits.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.